Muro K.Chung H.C.Shankaran V.Geva R.Catenacci D.Gupta S.Eder J.P.Golan T.Le D.T.Burtness B.McRee A.J.CHIA-CHI LINPathiraja K.Lunceford J.Emancipator K.Juco J.Koshiji M.Bang Y.-J.2022-09-152022-09-1520161470-2045https://www.scopus.com/inward/record.uri?eid=2-s2.0-84964779633&doi=10.1016%2fS1470-2045%2816%2900175-3&partnerID=40&md5=801461314208c42b1999996545de4e41https://scholars.lib.ntu.edu.tw/handle/123456789/620292[SDGs]SDG3Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trialjournal article10.1016/S1470-2045(16)00175-3271574912-s2.0-84964779633